Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 20:32 | 2026-03-30 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $590.59 | 9,500 | $5,610,564 | 40,513 |
| 2026-03-31 20:35 | 2026-03-27 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | SELL | $4.89 | 100,997 | $494,017 | 431,094 |
| 2026-03-31 20:20 | 2026-03-30 | ASMB | ASSEMBLY BIOSCIENCES, INC. | White Nicole S | Officer | SELL | $26.69 | 197 | $5,258 | 37,477 |
| 2026-03-31 20:21 | 2026-03-31 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | SELL | $65.00 | 3,639 | $236,535 | 66,004 |
| 2026-03-31 11:11 | 2026-03-27 | IMNM | Immunome Inc. | SIEGALL CLAY B | Director, Officer | BUY | $19.67 | 25,450 | $500,602 | 690,704 |
| 2026-03-30 21:29 | 2026-03-26 | XLO | Xilio Therapeutics, Inc. | Shannon James Samuel | Director | BUY | $8.79 | 5,000 | $43,950 | 10,000 |
| 2026-03-31 01:01 | 2026-03-26 | ROIV | Roivant Sciences Ltd. | Fitzgerald Meghan | Director | OPT+S | $27.45 | 70,000 | $1,921,500 | 42,963 |
| 2026-03-31 01:06 | 2026-03-25 | IBO | IMPACT BIOMEDICAL INC. | Macko Todd D | Officer | SELL | $0.56 | 45,000 | $25,331 | 155,122 |
| 2026-03-31 00:30 | 2026-03-26 | WVE | Wave Life Sciences Ltd. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | BUY | $6.23 | 8,772,496 | $54,624,578 | 26,975,505 |
| 2026-03-30 21:38 | 2026-03-26 | NGNE | Neurogene Inc. | Jordan Julie | Officer | SELL | $21.89 | 828 | $18,128 | 12,472 |
| 2026-03-30 21:38 | 2026-03-26 | NGNE | Neurogene Inc. | McMinn Rachel | Director, Officer | SELL | $22.07 | 3,352 | $73,995 | 1,344,307 |
| 2026-03-30 21:38 | 2026-03-26 | NGNE | Neurogene Inc. | Cvijic Christine Mikail | Officer | SELL | $21.62 | 2,558 | $55,316 | 103,240 |
| 2026-03-30 21:43 | 2026-03-26 | LQDA | Liquidia Corp | Bloch Stephen M | Director | SELL | $36.08 | 70,234 | $2,533,769 | 2,188,935 |
| 2026-03-30 21:29 | 2026-03-26 | CYPH | CYPHERPUNK TECHNOLOGIES INC. | Mirabelli Christopher | Director | SELL | $0.71 | 60,000 | $42,630 | 130,376 |
| 2026-03-30 21:31 | 2026-03-26 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | Officer | OPT+S | $98.73 | 5,500 | $542,991 | 59,634 |
| 2026-03-30 21:32 | 2026-03-27 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | Officer | SELL | $30.98 | 16,358 | $506,735 | 9,597 |
| 2026-03-27 20:05 | 2026-03-26 | IBIO | iBio, Inc. | Banjak Marc | Officer | BUY | $1.65 | 13,934 | $23,055 | 25,000 |
| 2026-03-28 00:06 | 2026-03-25 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Officer | OPT+S | $20.11 | 12,000 | $241,320 | 112,622 |
| 2026-03-28 00:15 | 2026-03-27 | ANAB | ANAPTYSBIO, INC | Faga Daniel | Director, Officer | SELL | $61.61 | 17,679 | $1,089,198 | 495,965 |
| 2026-03-27 23:33 | 2026-03-26 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | Officer | OPT+S | $104.24 | 24,765 | $2,581,504 | 60,753 |
| 2026-03-27 23:34 | 2026-03-26 | PTGX | Protagonist Therapeutics, Inc | SELICK HAROLD E | Director | OPT+S | $105.00 | 24,000 | $2,520,000 | 60,845 |
| 2026-03-27 23:36 | 2026-03-26 | PTGX | Protagonist Therapeutics, Inc | MOLINA ARTURO MD | Officer | OPT+S | $104.79 | 15,000 | $1,571,850 | 84,115 |
| 2026-03-27 22:17 | 2026-03-26 | CNTA | Centessa Pharmaceuticals plc | Anderson Karen M. | Officer | OPT+S | $30.12 | 41,076 | $1,237,382 | 62,085 |
| 2026-03-27 21:50 | 2026-03-25 | KALV | KalVista Pharmaceuticals, Inc. | Venrock Healthcare Capital Partners III, L.P. | 10% owner | SELL | $17.20 | 214,631 | $3,691,138 | 5,089,354 |
| 2026-03-27 20:57 | 2026-03-25 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Officer | OPT+S | $35.10 | 40,000 | $1,404,024 | 25,000 |
| 2026-03-27 20:44 | 2026-03-25 | TYRA | Tyra Biosciences, Inc. | KAPLAN GILLA | Director | OPT+S | $36.97 | 14,295 | $528,506 | 28,231 |
| 2026-03-27 20:25 | 2026-03-25 | LEGN | Legend Biotech Corp | Huang Ying | Director, Officer | SELL | $8.77 | 9,936 | $87,139 | 247,438 |
| 2026-03-27 20:27 | 2026-03-25 | CORT | CORCEPT THERAPEUTICS INC | BELANOFF JOSEPH K | Director, Officer | SELL | $50.07 | 26,198 | $1,311,826 | 2,918,326 |
| 2026-03-27 20:31 | 2026-03-26 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $535.90 | 10,000 | $5,359,005 | 18,876 |
| 2026-03-27 20:32 | 2026-03-26 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $535.81 | 9,500 | $5,090,216 | 40,513 |
| 2026-03-27 01:19 | 2026-03-24 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $55.21 | 21,120 | $1,166,105 | 52,200 |
| 2026-03-27 00:36 | 2026-03-26 | CNTA | Centessa Pharmaceuticals plc | Weinhoff Gregory M | Officer | OPT+S | $30.00 | 23,998 | $719,940 | 65,925 |
| 2026-03-27 00:00 | 2026-03-25 | ACAD | ACADIA PHARMACEUTICALS INC | Schneyer Mark C. | Officer | OPT+S | $21.55 | 7,385 | $159,136 | 60,269 |
| 2026-03-27 00:00 | 2026-03-25 | ACAD | ACADIA PHARMACEUTICALS INC | Kihara James | Officer | OPT+S | $21.57 | 1,942 | $41,895 | 26,885 |
| 2026-03-27 00:00 | 2026-03-25 | ACAD | ACADIA PHARMACEUTICALS INC | Rhodes Jennifer J | Officer | OPT+S | $21.47 | 3,844 | $82,531 | 11,280 |
| 2026-03-27 00:00 | 2026-03-25 | ACAD | ACADIA PHARMACEUTICALS INC | Thompson Elizabeth H.Z. | Officer | OPT+S | $21.47 | 3,435 | $73,749 | 3,280 |
| 2026-03-27 00:00 | 2026-03-25 | ACAD | ACADIA PHARMACEUTICALS INC | Owen Adams Catherine | Director, Officer | OPT+S | $21.47 | 11,641 | $249,932 | 14,803 |
| 2026-03-26 23:21 | 2026-03-25 | BCAX | Bicara Therapeutics Inc. | Raben David | Officer | OPT+S | $18.95 | 5,500 | $104,229 | 55,286 |
| 2026-03-26 22:00 | 2026-03-24 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Soteropoulos Paula | Director | OPT+S | $78.05 | 27,594 | $2,153,712 | 0 |
| 2026-03-26 21:39 | 2026-03-24 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | SELL | $5.56 | 17,909 | $99,506 | 532,091 |
| 2026-03-26 21:00 | 2026-03-24 | GNLX | GENELUX Corp | Zindrick Thomas | Officer | SELL | $2.42 | 3,582 | $8,668 | 534,849 |
| 2026-03-26 21:00 | 2026-03-24 | GNLX | GENELUX Corp | Yu Yong | Officer | SELL | $2.42 | 906 | $2,193 | 144,938 |
| 2026-03-26 21:00 | 2026-03-24 | GNLX | GENELUX Corp | Cappello Joseph | Officer | SELL | $2.42 | 906 | $2,193 | 155,154 |
| 2026-03-26 21:00 | 2026-03-24 | GNLX | GENELUX Corp | Smalling Ralph | Officer | SELL | $2.46 | 585 | $1,437 | 68,073 |
| 2026-03-26 20:34 | 2026-03-26 | UTHR | UNITED THERAPEUTICS Corp | Thompson Tommy G | Director | OPT+S | $539.17 | 2,000 | $1,078,332 | 8,480 |
| 2026-03-26 20:34 | 2026-03-25 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $543.73 | 9,500 | $5,165,475 | 40,513 |
| 2026-03-26 20:41 | 2026-03-25 | RAPP | Rapport Therapeutics, Inc. | Yeleswaram Krishnaswamy | Officer | SELL | $29.99 | 10,115 | $303,355 | 286,876 |
| 2026-03-26 20:30 | 2026-03-24 | NUVL | Nuvalent, Inc. | Balcom Alexandra | Officer | OPT+S | $98.15 | 25,130 | $2,466,610 | 85,533 |
| 2026-03-25 23:55 | 2026-03-23 | IBO | IMPACT BIOMEDICAL INC. | Grady Jason | Director | SELL | $0.65 | 50,000 | $32,505 | 250,182 |
| 2026-03-25 23:57 | 2026-03-13 | TLPH | TALPHERA, INC. | Angotti Vincent J. | Director, Officer | BUY | $0.59 | 213,310 | $125,000 | 800,705 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.